Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 19 of 604 for:    Recruiting, Not yet recruiting, Available Studies | Ovarian cancer

Imaging Study in Advanced Ovarian Cancer (ISAAC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03808792
Recruitment Status : Not yet recruiting
First Posted : January 18, 2019
Last Update Posted : January 18, 2019
Sponsor:
Information provided by (Responsible Party):
Ana Patrícia Pinto, Charles University, Czech Republic

Brief Summary:
The aim of the study is the assessment of tumour sites critical for the achievement of optimal cytoreduction in patients with advanced ovarian cancer using Ultrasound, CT and WB-DWI/MRI. The study uses an equivalence design with a hypothesis that cases with non-resectable disease identified by Index test (Ultrasound, CT and WB-DWI MRI) are equivalent to a portion of cases identified during surgery.

Condition or disease Intervention/treatment
Ovarian Cancer Diagnostic Test: Ultrasound, CT and WB-DWI/MRI

Detailed Description:

Patients with abdominal or pelvic mass suspicious of primary ovarian, tubal or peritoneal cancer using subjective assessment by experienced sonographer (principal investigator) will be enrolled in the study and send to surgical planning. During surgical planning, the CT and MRI will be scheduled and the patient ́s consent will be requested if inclusion criteria are fulfilled. Please note, tumors with atypical morphology and/or tumor spread suspicious for secondary ovarian cancer will be first subjected to a tru-cut biopsy and will be included if histopathology confirms adnexal or peritoneal cancer.

Ultrasound will be always performed by the principal investigator in each center. Principal investigator is an ultrasound expert with level II or III EFSUMB accreditation (http://www.efsumb.org/). Operators performing ultrasound scan and radiologists performing CT or MRI will be well instructed and educated about standardized approach and criteria of inoperability. Sonographers and radiologists will be blinded to the results of other imaging modalities. If a patient already had CT or WB-DWI/MRI done by the referring hospital, the study radiologists will decide about the quality of imaging and necessity to repeat CT or WB-DWI/MRI.

The decision to treat by PDS (primary debulking surgery), or by NACT (neoadjuvant chemotherapy) with IDS (interval debulking surgery) will be based on departmental guidelines taking into account medical comorbidities and disease-related factors. If a patient is indicated for NACT a tru-cut biopsy or/and a diagnostic laparoscopy are performed. The clinicians will document why the primary debulking surgery was not considered. The surgery (laparoscopy, primary or interval debulking surgery) should always be performed within four weeks after the index test. Patients without surgical exploration will be excluded.

Surgeons performing laparoscopy will describe site to site involvement and in case of inoperability will take a biopsy and document reasons for abandoning laparotomy. In operable cases surgeons performing laparotomy will describe site to site involvement and where applicable reasons for not achieving optimal cytoreduction defined as no residual tumor left in situ at the end of surgery (R0).

If the patient has only ultrasound and CT (and not WB-DWI/MRI) she can still be included in the study. Similarly if the patient undergoes interval debulking surgery she can be included in the study if the index tests will be performed less than 4 week before IDS.

Clinical data and four evaluation forms will be filled in (Ultrasound, CT, MRI, Surgery) immediately after the procedure using electronic database. The evaluation form from histopathology will be filled when available by principal investigator. The database cannot be saved unless all the information required are filled in and it will not be available to any other investigator. Data will be submitted for statistical analysis.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 400 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Comparison Between Ultrasound, CT (CT) and Whole-body Diffusion-weighted MRI (WB-DWI/MRI) in the Assessment of Operability in Patients With Ovarian Cancer
Estimated Study Start Date : January 2020
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 31, 2022


Group/Cohort Intervention/treatment
Ovarian cancer patients
Patients with abdominal or pelvic mass suspicious of primary ovarian, tubal or peritoneal cancer submitted to the index test (Ultrasound, CT and WB/DWI-MRI) with perspective of primary surgery
Diagnostic Test: Ultrasound, CT and WB-DWI/MRI
Preoperative assessment with Ultrasound, CT and WB-DWI/MRI




Primary Outcome Measures :
  1. Preoperative identification of patients with ovarian/tubal cancer in whom optimal debulking (R0/R1) can not be achieved by US and CT scan. [ Time Frame: 24 months ]
    Optimal debulking is defined as residual disease <1cm


Secondary Outcome Measures :
  1. Assessment of the diagnostic performance in the detection of involvement of individual sites relevant for clinical management and in the detection of 24 individual sites described in the evaluation form. [ Time Frame: 24 months ]
    1. Detection of involvement of individual sites relevant for clinical management:

      • Rectosigmoid
      • Colon (except ileocecum)
      • Ileocaecum
      • Lesser omentum
      • Small intestine
      • Liver
      • Diaphragm
      • Pleura
    2. Detection of 24 individual sites described in the evaluation form (17 peritoneal sites and 7 lymph nodes sites).

    The aim is to clarify the diagnostic performance of the different imaging methods in the assessment of tumor extent in form of peritoneal carcinomatosis and metastatic lymph nodes. The investigators want to establish the overall accuracy of each imaging modality in all the metastatic sites. The major interest lies in the sites that determine the extent of surgery and optimal cytoreduction, in particular bowel resection, lesser omentum, superficial liver metastases, diaphragm or pleura.


  2. Prediction model of achievement of optimal cytoreduction. [ Time Frame: 24 months ]
    Prediction of optimal cytoreduction based on preoperative imaging. Optimal cytoreduction is defined as no residual tumor left at the end of surgery (R0).

  3. Markers influencing accuracy - FIGO stage [ Time Frame: 24 months ]

    Assessment of markers influencing diagnostic accuracy of individual methods:

    FIGO stage - it will be analised if the accuracy of the imaging methods change between early stages (I-II) and late stages (III-IV) of the disease


  4. Markers influencing accuracy - Histological type [ Time Frame: 24 months ]

    Assessment of markers influencing diagnostic accuracy of individual methods:

    Histological type - it will be analised if the accuracy of the imaging methods change between serous type and other histological types


  5. Markers influencing accuracy - Origin [ Time Frame: 24 months ]
    Assessment of markers influencing diagnostic accuracy of individual methods: Origin - it will be analised if the accuracy of the imaging methods change between ovarian origin and tubal origin

  6. Markers influencing accuracy - Intraperitoneal fluid [ Time Frame: 24 months ]

    Assessment of markers influencing diagnostic accuracy of individual methods:

    Intraperitoenal fluid - it will be analised if the accuracy of the imaging methods change between < or = 400 mL and > 400 mL


  7. Markers influencing accuracy - Age [ Time Frame: 24 months ]

    Assessment of markers influencing diagnostic accuracy of individual methods:

    Age - it will be analised if the accuracy of the imaging methods change between women with < or = 65 and > 65 years old


  8. Markers influencing accuracy - CA 125 [ Time Frame: 24 months ]

    Assessment of markers influencing diagnostic accuracy of individual methods:

    CA 125 - it will be analised if the accuracy of the imaging methods change between < or = 300 U/mL and > 300 U/mL


  9. Markers influencing accuracy - Postmenopausal status [ Time Frame: 24 months ]

    Assessment of markers influencing diagnostic accuracy of individual methods:

    Postmenopausal status - it will be analised if the accuracy of the imaging methods change between premnopausal and postmenopausal status


  10. Markers influencing accuracy - Body mass index [ Time Frame: 24 months ]

    Assessment of markers influencing diagnostic accuracy of individual methods:

    Body mass índex - it will be analised if the accuracy of the imaging methods change between < or = 25 kg/m2 and > 25 kg/m2


  11. Markers influencing accuracy - Image quality [ Time Frame: 24 months ]

    Assessment of markers influencing diagnostic accuracy of individual methods:

    Image quality - it will be analised if the accuracy of the imaging methods change between good, moderate and poor image quality



Other Outcome Measures:
  1. Patient Method Friendly Questionnaire [ Time Frame: 24 months ]

    Evaluation of patients' experience of the imaging modalities using Patient Method Friendly Questionnaire.

    The aim of the questionnaire is to evaluate the overall experience through the different imaging methods and to evaluate relevant factors that may had a negative impact on the examination. The answers should be in a 4-point scale (1-very disappointing; 2-disappointing; 3- satisfied; 4-very satisfied) except the level of pain that should be in a 10-scale of pain (1 - no pain; 10 - maximum pain)


  2. Excluded patients [ Time Frame: 24 months ]

    Monitorization of excluded patients using an evaluation form filled by the principal investigator or study coordinator in each center. It has to be chosen one of the next options:

    1. Age <18 or > 80 years old
    2. Poor performance status ECOG >3
    3. Histologic report of biopsy of a non-gynecologic cancer
    4. Contraindications to upfront LPS or LPT (only tru-cut biopsy +/- NACT)
    5. Contraindications to CT
    6. Consent not given by the patient (denial or withdrawal of oral informed consent)
    7. Absence of insurance
    8. Time between ultrasound and surgery more than 4 weeks
    9. Current pregnancy
    10. Death
    11. Others, please specify:

  3. Record of choice of treatment [ Time Frame: 24 months ]
    Record of multidisciplinary team choice of primary surgery or neoadjuvant chemotherapy to clarify personal and external factors in decision making



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Female patients
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with an abdominal or pelvic mass suspicious of primary ovarian, tubal or peritoneal cancer
Criteria

Inclusion Criteria:

  1. Abdominal or pelvic mass suspicious of primary ovarian, tubal or peritoneal cancer using subjective assessment by experienced sonographer.
  2. Surgery (PDS or IDS) within 4 weeks from the index test.
  3. 18 > Age < 80.
  4. ECOG (Eastern Cooperative Oncology Group) grade < 3.
  5. Patients after NACT can be included.

Exclusion Criteria:

  1. Lesions suspected as being borderline ovarian tumors (BOT) on ultrasound.
  2. Patients with supradiaphragmatic metastases
  3. Contraindications to CT
  4. Medical contraindications to surgery
  5. Refusal or withdrawal of written informed consent
  6. Time lapse between ultrasound and surgery more than 4 weeks
  7. Current pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03808792


Contacts
Layout table for location contacts
Contact: Patrícia Pinto, MD +351912414130 aplpinto@gmail.com
Contact: Daniela Fischerová, MD, PhD +420603285097 daniela.fischerova@seznam.cz

Locations
Layout table for location information
Czechia
Gynecologic Oncology Center in Prague Not yet recruiting
Prague, Czechia, 15000
Contact: Daniela Fischerová, MD, PhD    +420603285097    daniela.fischerova@seznam.cz   
Sponsors and Collaborators
Charles University, Czech Republic
Investigators
Layout table for investigator information
Study Chair: Daniela Fischerová, MD, PhD Gynecologic Oncology Center, Department of Obstetrics and Gynecology, General University Hospital in Prague and 1st Medical Faculty of the Charles University, Prague, Czech Republic

Layout table for additonal information
Responsible Party: Ana Patrícia Pinto, Principal Investigator, Charles University, Czech Republic
ClinicalTrials.gov Identifier: NCT03808792     History of Changes
Other Study ID Numbers: č.j. 29/18
First Posted: January 18, 2019    Key Record Dates
Last Update Posted: January 18, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ana Patrícia Pinto, Charles University, Czech Republic:
Ovarian cancer
Ultrasound
CT
WB-DW/MRI
Imaging
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Adnexal Diseases
Genital Diseases, Female
Endocrine System Diseases
Gonadal Disorders
Carcinoma